Combined effects of Ret coding and enhancer loss-of-function alleles cause progressive loss of inhibitory motor neurons in the enteric nervous system

Hirschsprung disease (HSCR) is a congenital disorder of the enteric nervous system (ENS)—the vast, intrinsic network of neurons that governs gastrointestinal motility. In affected individuals, the absence of these neurons along parts of the bowel prevents normal movement. While scientists have long known that mutations in the RET gene can cause this condition, a massive piece of the puzzle has remained missing. Why do common, non-coding variants—genetic "switches" that do not change the protein itself but merely regulate how much of it is made—contribute so heavily to disease risk?

Current understanding suggests that HSCR is often not the result of a single catastrophic mutation. Instead, it may be a cumulative "dosage" problem. Researchers have suspected that a combination of rare mutations in the RET coding sequence and common variants in nearby enhancers (regulatory DNA elements that control gene expression levels) might push the system below a critical functional threshold. However, it has been unclear which specific cell types are most vulnerable to these subtle shifts in gene dosage. It has also been unknown how a slight reduction in RET translates into the physical absence of nerve cells.

The missing threshold in enteric development

The prevailing model of HSCR research has struggled to reconcile two different genetic architectures. On one hand, high-penetrance coding mutations fundamentally break the RET protein. On the other, low-penetrance non-coding variants merely dial down the volume of RET expression. Previous studies, such as those focusing on Ret null (completely inactive) mice, showed that total loss of the gene leads to massive aganglionosis (the total absence of enteric ganglia). Yet, simple heterozygous mice—those with only one working copy of the gene—typically develop normally.

This creates a theoretical gap. If a 50% reduction in RET is tolerated in a heterozygote, what is the exact tipping point where the system fails? Furthermore, the field has lacked a way to determine if these regulatory variants act globally across all gut cells. Or do they target specific, sensitive lineages? Without knowing the "who" and the "how much," clinicians cannot fully predict how a patient's unique mix of coding and non-coding variants will manifest as disease.

Decoding the additive effect of regulatory loss

To bridge this gap, the authors employed a strategy of "compounding" genetic hits to simulate the complex reality of human patients. They did not just look at one mutation. They built a multi-layered model to observe the progressive collapse of the system. Their approach followed three logical stages:

1. Isolating the Enhancer: The researchers first targeted the mcs+9.7 enhancer. This is the mouse ortholog of a human element known to bind the transcription factor SOX10 (a protein that controls the expression of other genes). Using CRISPR/Cas9, they generated mice with a 183-bp deletion ($\Delta mcs+9.7$) to see if removing this "volume knob" alone would cause disease.
2. Simulating Compound Heterozygosity: Humans often carry both coding and non-coding variants. To mimic this, they crossed these enhancer-deleted mice with Ret+/CFP mice (which carry a coding null allele). This created "+/$\Delta mcs+9.7$;+/CFP" mice. These effectively simulated a patient with both a broken gene and a faulty regulator.
3. High-Resolution Mapping: They used single-cell RNA sequencing (scRNA-seq) to profile over 60,000 cells from the E14.5 embryonic gut. This allowed them to move beyond looking at the "whole gut." They could instead zoom in on specific cell identities, such as inhibitory motor neurons or glial progenitors.

As shown in, the enhancer deletion alone was surprisingly mild.

It reduced Ret expression by only about 6% in the homozygous $\Delta mcs+9.7/\Delta mcs+9.7$ mice. However, when combined with the coding mutation, the reduction became additive and dramatic.

Crossing the 50% functional threshold

The central finding of the study is that HSCR is a threshold-driven disease. The authors report that while a single coding mutation leaves Ret at ~50% of wild-type levels, the addition of the enhancer deletion pushes expression down to approximately 42% in the embryonic gut [Figure 1B]. This 8% drop below the half-way mark is critical. It is precisely this dip below the 50% threshold that triggers a cascade of cellular failures.

The consequences are not uniform across the ENS. Through single-cell analysis, the authors demonstrate that the loss is highly cell-type specific. While the overall composition of the gut remains largely stable in the enhancer-only mutants [Figure 2B], the compound heterozygotes show a selective and profound depletion of specific lineages. Most notably, the authors find a 39% reduction in inhibitory motor neurons (iMNs) and a 34% reduction in differentiating neurons and glia [Figure 3C].

To validate these transcriptomic findings in a living tissue context, the researchers used RNAscope (a method for visualizing specific RNA molecules in situ). They confirmed that in the compound mutants, the density of Nos1 and Vip—markers for inhibitory motor neurons—was slashed by 46% and 58%, respectively [Figure 5D]. Crucially, this was not just a case of cells "turning off" their markers. The cells themselves were physically disappearing.

Mechanisms of lineage-specific depletion

Why are inhibitory motor neurons the "canary in the coal mine"? The authors identify two reinforcing mechanisms that make this lineage uniquely vulnerable to Ret dosage drops.

First, they discovered a cell-type-specific positive feedback loop between Ret and its regulator, Sox10. In iMNs, reduced Ret leads to a concomitant reduction in Sox10 expression [Figure 3E]. This creates a downward spiral. Less Ret means less Sox10. This, in turn, further destabilizes the regulatory program required to maintain that cell identity.

Second, the reduction in Ret directly impairs the cell cycle (the process of cell division). The authors report that in the iMN lineage of compound heterozygotes, there is a significant downregulation of genes responsible for mitosis (cell division) and DNA replication. These include Ccnb1, Cdk1, and Top2a [Figure 6B]. They validated this by showing a 46% decrease in the colocalization of the neuronal marker Nos1 with the proliferation marker Mki67 [Figure 6D]. Essentially, the cells are failing to divide fast enough to populate the developing gut. This leads to the eventual "void" characteristic of aganglionosis.

Limitations and the road ahead

While this study provides a robust mechanistic link, it is not without limitations. The research focused exclusively on the E14.5 embryonic stage. This is a critical window for ENS colonization. Consequently, the authors cannot definitively say how these early molecular perturbations evolve into late-stage postnatal pathologies. They also cannot rule out how these changes might affect long-term gut homeostasis.

Furthermore, there is a noted discrepancy between mouse models and human biology. Recent studies of human patient-derived cells suggest that certain progenitor populations might be entirely absent in humans. This feature has not yet been replicated in mouse models. This suggests that while the Ret dosage threshold is a universal principle, the specific "cellular casualties" might vary between species.

The verdict: A threshold-based model of disease

The evidence presented here is compelling. HSCR is best understood not as a binary "on/off" switch, but as a quantitative failure of a developmental program. By demonstrating that the $mcs+9.7$ enhancer acts as a critical modifier, the authors have provided a definitive explanation for the variable penetrance seen in human families. The selective loss of inhibitory motor neurons due to disrupted cell-cycle programs and Sox10 feedback loops offers a clear mechanism. It shows how subtle genetic variations culminate in profound clinical disease.

Figures from the paper